On November 12, 2026 Artelo Biosciences, Inc. (Nasdaq: ARTL) ("Artelo" or the "Company"), a clinical stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, obesity, dermatologic, ophthalmic, and neurological conditions, reported a business update and announced its financial and operational results for the third quarter ended September 30, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Business Highlights

ART27.13:

Expanding Development Opportunities in Obesity: New nonclinical findings demonstrated approximately 20% weight loss with ART27.13 monotherapy, comparable to semaglutide, and approximately 40% weight loss when combined with semaglutide in a diet-induced obesity animal model. The combination also further improved oral glucose tolerance and increased bone mineral density, effects not observed in any other treatment group. The results support ART27.13’s potential as a treatment for obesity, both independently and in combination with GLP-1 therapies, expanding beyond cancer supportive care towards a total weight management solution.
Strengthening Intellectual Property and Clinical Potential: Artelo filed a provisional patent application covering ART27.13 for obesity and combination use with GLP-1 receptor agonists. Artelo also received Notices of Allowance in the U.S. and Japan for patent claims covering the intended commercial formulation of ART27.13. The U.S. patent, once issued, is expected to extend protection through 2041. The Company continues to pursue multiple indications, supported by previously reported Phase 2 CAReS interim findings demonstrating improvements in body weight, lean body mass and physical activity in patients experiencing cancer-related anorexia and weight loss.
Second Phase 2 Study Initiated in Glaucoma: Enrollment is already underway for the investigator-led DREAM trial, a Phase 2 study evaluating whether oral daily treatment with ART27.13 can lower intraocular pressure in people with glaucoma or ocular hypertension.

ART26.12:

Advancing First-in-Human FABP5 Inhibitor for Non-Opioid Pain Treatment: Plans for ART26.12, the first selective fatty acid binding protein 5 (FABP5) inhibitor evaluated in humans, anticipate a Phase 1 multiple ascending dose (MAD) study to initiate in the fourth quarter of 2026. Previously reported single ascending dose results demonstrated favorable safety and tolerability, predictable pharmacokinetics and exposure levels supporting further clinical development.
Strengthening Scientific Evidence and Industry Engagement: Artelo presented ART26.12 data at the International Association for the Study of Pain (IASP) 2026 World Congress on Pain and at BIO-Europe 2026, highlighting its differentiated mechanism of action and potential to address significant unmet needs in chronic pain. Reported nonclinical findings indicate ART26.12’s potential across multiple pain indications, including chemotherapy-induced peripheral neuropathy, spinal cord injury and osteoarthritis, where it achieved pain relief levels comparable to naproxen with significantly less gastric tissue damage.

"We are gratified that our programs are moving closer to key clinical milestones and revealing new development opportunities," said Gregory D. Gorgas, President and Chief Executive Officer. "Our immediate priority is advancing ART26.12 into its next stage of clinical testing, where we aim to amplify the encouraging results observed to date. At the same time, the expanding potential of ART27.13 is generating opportunities with potential strategic partners in significant new therapeutic markets."

Q3 2026 Financial Results

R&D Expenses: Research and development expenses were $0.8 million for the quarter ended September 30, 2026, compared to $1.3 million for the quarter ended September 30, 2025.
G&A Expenses: General and administrative expenses were $1.0 million for the quarter ended September 30, 2026, compared to $1.8 million in the quarter ended September 30, 2025.
Net Loss: For the quarter ended September 30, 2026, net loss was $1.8 million, or $3.19 per basic and diluted common share, compared to a net loss of $3.1 million for the quarter ended September 30, 2025.
Cash and Investments: Cash totaled $4.4 million as of September 30, 2026.

(Press release, Artelo Biosciences, NOV 12, 2026, View Source [SID1234674728])